Chelation Therapy
The term chelation is from the Greek root word "chele," meaning "claw." Chelating agents, most commonly diamine tetraacetic acid (EDTA), were originally designed for industrial applications in the early 1900s. However, varieties of chelation agents are available and should be carefully chosen for the specific toxin(s) that must be removed. Chelation therapy also removes various nutrients including zinc; a deficiency of which can reduce immune function. Our office bases chelation therapy upon kidney function, the toxin or toxins (i.e., heavy metal) to be removed, medications, overall health and presence of disease…and very importantly, our patent pending laboratory interpretation technology – Blood Detective (please consult the rest of our brochure for more information).
WHAT YOU MUST KNOW
WE DO NOT give every patient the same chelation formula in their IV-drips; in fact, it is not uncommon for us to continuously change and adapt your IV-drip based on your progress, new research and your clinical response. This level of attention to your needs is what you will get and deserve! The “best chelator” does not exist – the chelator of choice may change, remain the same and or be combined with other necessary assessment measurements. Arterial stiffness (atherosclerosis measurement) and blood minerals and organ function measurements are just some of the testing possibilities for those who will receive chelation therapy.
ncbi.nlm.nih.gov/pubmed/17604460 There are increased risk of blood clots, leading to myocardial infarction and sudden death beginning six months after medicated stents are implanted in patients following percutaneous transluminal coronary angioplasty. Intravenous EDTA may be safe and effective for treating patients who have implanted medicated stents. There is evidence supporting EDTA chelation therapy and its possible prevention of hypercoagulability.
ncbi.nlm.nih.gov/pubmed/16536881 Chelation therapy with sodium edetate (EDTA) improved renal function and slowed the progression of renal insufficiency in patients subjected to lead intoxication. This data provides evidence that EDTA treatment is able to protect rat kidneys from ischemic damage possibly through the stimulation of NO production.
ncbi.nlm.nih.gov/pubmed/19946446 This study reports the usefulness of chelation therapy for the remission of symptoms caused by previous treatment with mercury-containing pharmaceuticals: a case report.
ncbi.nlm.nih.gov/pubmed/20981690 This study reports the safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. The study demonstrated a significant decrease in liver iron burden with high dose intermittent IV DFO.
ncbi.nlm.nih.gov/pubmed/18219211 Integrative medicine and the role of modified citrus pectin/alginates in heavy metal chelation and detoxification. Five case studies show the reduction of heavy metal toxicity by modified citrus pectin.
ncbi.nlm.nih.gov/pubmed/15917185 This study demonstrates that multiple sessions of EDTA chelation therapy protect lipids against oxidative damage. Furthermore, standard high amounts of vitamin C added to EDTA chelation solutions also display short-term prooxidant effects.
ncbi.nlm.nih.gov/pubmed/20413561 This study suggests that glutathione administration with EDTA might be an effective treatment modality for patients with cadmium intoxication.
ncbi.nlm.nih.gov/pubmed/20379455 This study suggests that the combination of EDTA chelation, phototherapeutic keratectomy and amniotic membrane transplantation is safe and effective for the treatment of band keratopathy (a non inflammatory disease of the cornea).
ncbi.nlm.nih.gov/pubmed/6441110 This study suggests that the introduction of EDTA chelation and multi-vitamin-trace mineral therapy improved renal function and creatinine clearance significantly improved.
ncbi.nlm.nih.gov/pubmed/20561034 This study suggests that the new chelation regimes, together with cardiac magnetic resonance (CMR) have contributed significantly to the reduction in cardiac morbidity and mortality in patients with thalassaemia.
ncbi.nlm.nih.gov/pubmed/17408840 This study reports the role of thiols, dithiols, nutritional factors and interacting ligands in the toxicology of mercury. It suggests that Alpha-lipoic acid (ALA), a disulfide, and its metabolite dihydrolipoic acid (DHLA), a dithiol, have also been shown to have chelation properties when used in an appropriate manner.
ncbi.nlm.nih.gov/pubmed/17394994 This article reports a successful treatment of potentially fatal heavy metal poisonings.
ncbi.nlm.nih.gov/pubmed/20835752 This study reviews quercetin within the presence of EDTA inhibits quercetin oxidation.
ncbi.nlm.nih.gov/pubmed/19553011 This study reports that EDTA (ethylenediaminetetraaceticacid) was used as a chelating agent to extract the Nickel.
ncbi.nlm.nih.gov/pubmed/19206210 This study suggests that chelation with EDTA stabilizes the structure of both wild-type rhodopsin and the most prevalent rhodopsin RP mutation, P(23)H.
AMERICAN HEART ASSOCIATION- http://www.heart.org/HEARTORG/
